← Leaderboards
Daniele Piomelli
University Of California Irvine
$28,091,294
Attributed
$29,742,059
Total exposure
23
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,259,328 · 24
By mechanism
P50$18,121,496 · 5
R01$11,884,546 · 6
DP1$3,703,518 · 1
RF1$2,328,624 · 1
R21$2,217,273 · 4
R42$1,498,471 · 1
Most similar at University Of California Irvine
Same institution · by research overlap
- Robert A Burger$607,680
- Shao-Jun Tang$14,497,589
- John J Krolewski$4,496,359
- Christine M Gall$14,021,008
- Gary S Lynch$10,176,242
Others in their field
Top investigators on “Brain”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Michael W Weiner · Northern California Institute Res &Educ$149,959,854
- David A Bennett · Rush University Medical Center$148,375,056
- David Heimbrook · Leidos Biomedical Research, Inc.$145,442,397
- Walter John Curran · Thomas Jefferson University$114,442,832
- Hongkui Zeng · Allen Institute$113,960,965
Research focus
BrainMolecularSignal TransductionCannabinoid ReceptorEndocannabinoidsBaseInnovationMediatingAnandamideBehaviorCannabinoidsResponseRattusRegulationResearch StudyEnzymesNeuronsBehavioralAddictionFatty Acid Amide HydrolasePositioning AttributeGeneticPlayExposure To
Grant awards (95)
Impact of Cannabinoid Across the Lifespan (ICAL)$2,366,309
P50 · FY2025 · DA · contact PI
Impact of Cannabinoid Across the Lifespan (ICAL)$592,501
P50 · FY2025 · DA · contact PI
The lipid hydrolase NAAA as a target for non-addictive analgesic medications$541,998
R01 · FY2025 · DA · contact PI
Impact of Cannabinoid Across the Lifespan (ICAL)$250,284
P50 · FY2025 · DA · contact PI
Impact of Cannabinoid Across the Lifespan (ICAL)$2,338,658
P50 · FY2024 · DA · contact PI
Impact of Cannabinoid Across the Lifespan (ICAL)$592,501
P50 · FY2024 · DA · contact PI
The lipid hydrolase NAAA as a target for non-addictive analgesic medications$576,282
R01 · FY2024 · DA · contact PI
The lipid amidase NAAA as a therapeutic target for Alzheimer's disease$575,906
R01 · FY2024 · AG · contact PI
Impact of Cannabinoid Across the Lifespan (ICAL)$201,448
P50 · FY2024 · DA · contact PI
The lipid hydrolase NAAA as a target for non-addictive analgesic medications$585,262
R01 · FY2023 · DA · contact PI
Allosteric control of monoacylglyceride lipase (MGL) activity$171,750
R21 · FY2023 · DA · contact PI
Allosteric control of monoacylglyceride lipase (MGL) activity$225,250
R21 · FY2022 · DA · contact PI
ICAL: Impact of Cannabinoids Across Lifespan$2,184,221
P50 · FY2021 · DA · contact PI
ICAL: Impact of Cannabinoids Across Lifespan: Molecular Project$426,537
P50 · FY2021 · DA · contact PI
ICAL: Impact of Cannabinoids Across Lifespan: Administrative Core$316,754
P50 · FY2021 · DA · contact PI
ICAL: Impact of Cannabinoids Across Lifespan$27,632
P50 · FY2021 · DA · contact PI
ICAL: Impact of Cannabinoids Across Lifespan$9,106
P50 · FY2021 · DA · contact PI
The lipid amidase NAAA as a therapeutic target for Alzheimer's disease$2,328,624
RF1 · FY2020 · AG · contact PI
ICAL: Impact of Cannabinoids Across Lifespan$2,181,939
P50 · FY2020 · DA · contact PI
ICAL: Impact of Cannabinoids Across Lifespan: Molecular Project$427,390
P50 · FY2020 · DA · contact PI
ICAL: Impact of Cannabinoids Across Lifespan: Administrative Core$313,619
P50 · FY2020 · DA · contact PI
ICAL: Impact of Cannabinoids Across Lifespan$2,239,680
P50 · FY2019 · DA · contact PI
ICAL: Impact of Cannabinoids Across Lifespan: Molecular Project$426,537
P50 · FY2019 · DA · contact PI
Peripheral FAAH as a target for novel analgesics$398,227
R42 · FY2019 · DA · contact PI
ICAL: Impact of Cannabinoids Across Lifespan: Administrative Core$316,593
P50 · FY2019 · DA · contact PI
ICAL: Impact of Cannabinoids Across Lifespan$2,169,724
P50 · FY2018 · DA · contact PI
ICAL: Impact of Cannabinoids Across Lifespan: Molecular Project$426,537
P50 · FY2018 · DA · contact PI
ICAL: Impact of Cannabinoids Across Lifespan: Administrative Core$313,526
P50 · FY2018 · DA · contact PI
Peripheral FAAH inhibitor, URB937, as an opioid-sparing analgesic for chronic pain.$225,000
R41 · FY2018 · NS · contact PI
Peripheral FAAH as a target for novel analgesics$1,100,244
R42 · FY2017 · DA · contact PI
A Protective role for 2-AG in age-dependent cognitive impairment.$193,125
R21 · FY2017 · AG · contact PI
Lipidomics analysis of identified single neurons in the adult rodent brain$193,125
R21 · FY2017 · DA · contact PI
Lipidomics analysis of identified single neurons in the adult rodent brain$8,467
R21 · FY2017 · DA · contact PI
Characterization of Anandamide Transport in Brain$301,969
R01 · FY2016 · DA · contact PI
A Protective role for 2-AG in age-dependent cognitive impairment.$231,750
R21 · FY2016 · AG · contact PI
Lipidomics analysis of identified single neurons in the adult rodent brain$193,125
R21 · FY2016 · DA · contact PI
Characterization of Anandamide Transport in Brain$8,467
R01 · FY2016 · DA · contact PI
Characterization of Anandamide Transport in Brain$300,444
R01 · FY2015 · DA · contact PI
A new treatment for NSAID-associated gastrointestinal damage$150,000
R41 · FY2015 · DK · contact PI
Characterization of Anandamide Transport in Brain$13,720
R01 · FY2015 · DA · contact PI
Optimization and preclinical development of FAAH inhibitors for smoking cessation$742,050
DP1 · FY2014 · DA · contact PI
Characterization of Anandamide Transport in Brain$305,020
R01 · FY2014 · DA · contact PI
Characterization of Anandamide Transport in Brain$5,508
R01 · FY2014 · DA · contact PI
Optimization and preclinical development of FAAH inhibitors for smoking cessation$712,368
DP1 · FY2013 · DA · contact PI
Characterization of Anandamide Transport in Brain$291,917
R01 · FY2013 · DA · contact PI
Characterization of Anandamide Transport in Brain$7,560
R01 · FY2013 · DA · contact PI
Optimization and preclinical development of FAAH inhibitors for smoking cessation$742,050
DP1 · FY2012 · DA · contact PI
Characterization of Anandamide Transport in Brain$299,351
R01 · FY2012 · DA · contact PI
Optimization and preclinical development of FAAH inhibitors for smoking cessation$742,050
DP1 · FY2011 · DA · contact PI
Role of endocannabinoid signaling in stress-coping behavior$220,660
RL1 · FY2011 · AA · contact PI
Optimization and preclinical development of FAAH inhibitors for smoking cessation$765,000
DP1 · FY2010 · DA · contact PI
Lipid biosignatures of drug addiction$530,178
RC2 · FY2010 · DA · contact PI
Characterization of a novel brain cannabinoid ligand$354,192
R01 · FY2010 · DA · contact PI
Role of oleoylethanolamide in the control of food intake$296,639
R01 · FY2010 · DK · contact PI
Role of endocannabinoid signaling in stress-coping behavior$222,889
RL1 · FY2010 · AA · contact PI
Lipid biosignatures of drug addiction$560,558
RC2 · FY2009 · DA · contact PI
Characterization of a novel brain cannabinoid ligand$351,089
R01 · FY2009 · DA · contact PI
Role of oleoylethanolamide in the control of food intake$289,705
R01 · FY2009 · DK · contact PI
Role of endocannabinoid signaling in stress-coping behavior$225,140
RL1 · FY2009 · AA · contact PI
Role of oleoylethanolamide in the control of food intake$99,992
R01 · FY2009 · DK · contact PI
Role of endocannabinoid signaling in stress-coping behavior$19,000
RL1 · FY2009 · AA · contact PI
Characterization of anandamide transport in brain$388,396
R01 · FY2008 · DA · contact PI
Role of Endocannabinoids in the Behavioral Consequences of Social Isolation$326,512
R21 · FY2008 · DA · contact PI
Role of oleoylethanolamide in the control of food intake$307,128
R01 · FY2008 · DK · contact PI
Characterization of a novel cannabinoid ligand$283,411
R01 · FY2008 · DA · contact PI
Role of endocannabinoid signaling in stress-coping behavior$224,404
RL1 · FY2008 · AA · contact PI
Characterization of anandamide transport in brain$384,775
R01 · FY2007 · DA · contact PI
Role of Endocannabinoids in the Behavioral Consequences of Social Isolation$331,421
R21 · FY2007 · DA · contact PI
Role of oleoylethanolamide in the control of food intake$324,706
R01 · FY2007 · DK · contact PI
Characterization of a novel cannabinoid ligand$289,195
R01 · FY2007 · DA · contact PI
Role of endocannabinoid signaling in stress-coping behavior$220,875
RL1 · FY2007 · AA · contact PI
Characterization of anandamide transport in brain$26,352
R01 · FY2007 · DA · contact PI
Characterization of anandamide transport in brain$384,724
R01 · FY2006 · DA · contact PI
Role of Endocannabinoids in the Behavioral Consequences of Social Isolation$342,748
R21 · FY2006 · DA · contact PI
Characterization of a novel cannabinoid ligand$297,833
R01 · FY2006 · DA · contact PI
Characterization of anandamide transport in brain$382,509
R01 · FY2005 · DA
Characterization of a novel cannabinoid ligand$304,166
R01 · FY2005 · DA
Oleylethanolamide derivatives as anti-obesity agents$100,000
R41 · FY2005 · DK
THE NEUROBIOLOGY OF SUBSTANCE ABUSE$8,121
T32 · FY2005 · DA
Characterization of anandamide transport in brain$427,776
R01 · FY2004 · DA
THE NEUROBIOLOGY OF SUBSTANCE ABUSE$208,066
T32 · FY2004 · DA
CONTROL OF ENDOCANNABINOID RELEASE IN VIVO$306,045
R01 · FY2003 · DA
THE NEUROBIOLOGY OF SUBSTANCE ABUSE$174,923
T32 · FY2003 · DA
CONTROL OF ENDOCANNABINOID RELEASE IN VIVO$8,532
R01 · FY2003 · DA
ANANDAMIDE TRANSPORT IN BRAIN$403,243
R01 · FY2002 · DA
CONTROL OF ENDOCANNABINOID RELEASE IN VIVO$297,132
R01 · FY2002 · DA
THE NEUROBIOLOGY OF SUBSTANCE ABUSE$216,172
T32 · FY2002 · DA
NOVEL BRAIN CANNABINOID LIGAND$168,200
R01 · FY2002 · DA
ANANDAMIDE TRANSPORT IN BRAIN$391,498
R01 · FY2001 · DA
CONTROL OF ENDOCANNABINOID RELEASE IN VIVO$288,476
R01 · FY2001 · DA
THE NEUROBIOLOGY OF SUBSTANCE ABUSE$199,414
T32 · FY2001 · DA
NOVEL BRAIN CANNABINOID LIGAND$163,303
R01 · FY2001 · DA
ANANDAMIDE TRANSPORT IN BRAIN$413,506
R01 · FY2000 · DA
CONTROL OF ENDOCANNABINOID RELEASE IN VIVO$280,073
R01 · FY2000 · DA
NOVEL BRAIN CANNABINOID LIGAND$158,546
R01 · FY2000 · DA